# EDGAR Filing Document

**Accession Number:** 0001134655
**File Stem:** 0001231919-25-000459
**Filing Date:** 2025-11
**Character Count:** 20564
**Document Hash:** f46996abdcf8524c308250cc2cafaa95
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001231919-25-000459.hdr.sgml**: 20251112

**ACCESSION NUMBER**: 0001231919-25-000459

**CONFORMED SUBMISSION TYPE**: 4

**PUBLIC DOCUMENT COUNT**: 1

**CONFORMED PERIOD OF REPORT**: 20251107

**FILED AS OF DATE**: 20251112

**DATE AS OF CHANGE**: 20251112

**REPORTING-OWNER**: 

**OWNER DATA:**
- **COMPANY CONFORMED NAME:** GADICKE ANSBERT
- **CENTRAL INDEX KEY:** 0001134655

**ORGANIZATION NAME:**

**FILING VALUES:**
- **FORM TYPE:** 4
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-40366
- **FILM NUMBER:** 251474897

**MAIL ADDRESS:**
- **STREET 1:** 399 BOYLSTON STREET
- **STREET 2:** SUITE 1100
- **CITY:** BOSTON
- **STATE:** MA
- **ZIP:** 02116
**REPORTING-OWNER**: 

**OWNER DATA:**
- **COMPANY CONFORMED NAME:** MPM ASSET MANAGEMENT LLC
- **CENTRAL INDEX KEY:** 0001263048

**ORGANIZATION NAME:**
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** 4
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-40366
- **FILM NUMBER:** 251474891

**BUSINESS ADDRESS:**
- **STREET 1:** 399 BOYLSTON STREET, SUITE 1100
- **CITY:** BOSTON
- **STATE:** MA
- **ZIP:** 02116
- **BUSINESS PHONE:** 6174259200

**MAIL ADDRESS:**
- **STREET 1:** 399 BOYLSTON STREET, SUITE 1100
- **CITY:** BOSTON
- **STATE:** MA
- **ZIP:** 02116
**REPORTING-OWNER**: 

**OWNER DATA:**
- **COMPANY CONFORMED NAME:** MPM BioImpact LLC
- **CENTRAL INDEX KEY:** 0001687078

**ORGANIZATION NAME:**
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** 4
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-40366
- **FILM NUMBER:** 251474893

**BUSINESS ADDRESS:**
- **STREET 1:** 399 BOYLSTON STREET, SUITE 1100
- **CITY:** BOSTON
- **STATE:** MA
- **ZIP:** 02116
- **BUSINESS PHONE:** 6174259200

**MAIL ADDRESS:**
- **STREET 1:** 399 BOYLSTON STREET, SUITE 1100
- **CITY:** BOSTON
- **STATE:** MA
- **ZIP:** 02116

**FORMER NAME:**
- **FORMER CONFORMED NAME:** BioImpact Capital LLC
- **DATE OF NAME CHANGE:** 20210831

**FORMER NAME:**
- **FORMER CONFORMED NAME:** MPM Oncology Impact Management LP
- **DATE OF NAME CHANGE:** 20161007
**REPORTING-OWNER**: 

**OWNER DATA:**
- **COMPANY CONFORMED NAME:** MPM Oncology Innovations Fund GP LLC
- **CENTRAL INDEX KEY:** 0001857903

**ORGANIZATION NAME:**
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** 4
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-40366
- **FILM NUMBER:** 251474892

**BUSINESS ADDRESS:**
- **STREET 1:** C/O MPM BIOIMPACT
- **STREET 2:** 399 BOYLSTON STREET, SUITE 1100
- **CITY:** BOSTON
- **STATE:** MA
- **ZIP:** 02116
- **BUSINESS PHONE:** 617-425-9200

**MAIL ADDRESS:**
- **STREET 1:** C/O MPM BIOIMPACT
- **STREET 2:** 399 BOYLSTON STREET, SUITE 1100
- **CITY:** BOSTON
- **STATE:** MA
- **ZIP:** 02116
**REPORTING-OWNER**: 

**OWNER DATA:**
- **COMPANY CONFORMED NAME:** MPM ONCOLOGY INNOVATIONS FUND LP
- **CENTRAL INDEX KEY:** 0001719960

**ORGANIZATION NAME:**
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** 4
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-40366
- **FILM NUMBER:** 251474896

**BUSINESS ADDRESS:**
- **STREET 1:** 450 KENDALL STREET
- **CITY:** CAMBRIDGE
- **STATE:** MA
- **ZIP:** 02142
- **BUSINESS PHONE:** 617-425-9200

**MAIL ADDRESS:**
- **STREET 1:** 450 KENDALL STREET
- **CITY:** CAMBRIDGE
- **STATE:** MA
- **ZIP:** 02142

**FORMER NAME:**
- **FORMER CONFORMED NAME:** MPM ONCOLOGY INNOVATIONS FUND L.P.
- **DATE OF NAME CHANGE:** 20171017
**REPORTING-OWNER**: 

**OWNER DATA:**
- **COMPANY CONFORMED NAME:** Oncology Impact Fund (Cayman) Management L.P.
- **CENTRAL INDEX KEY:** 0001721036

**ORGANIZATION NAME:**
- **STATE OF INCORPORATION:** E9
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** 4
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-40366
- **FILM NUMBER:** 251474894

**BUSINESS ADDRESS:**
- **STREET 1:** 450 KENDALL STREET
- **CITY:** CAMBRIDGE
- **STATE:** MA
- **ZIP:** 02142
- **BUSINESS PHONE:** 6174259200

**MAIL ADDRESS:**
- **STREET 1:** 450 KENDALL STREET
- **CITY:** CAMBRIDGE
- **STATE:** MA
- **ZIP:** 02142
**REPORTING-OWNER**: 

**OWNER DATA:**
- **COMPANY CONFORMED NAME:** UBS Oncology Impact Fund L.P.
- **CENTRAL INDEX KEY:** 0001691428

**ORGANIZATION NAME:**
- **STATE OF INCORPORATION:** E9
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** 4
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-40366
- **FILM NUMBER:** 251474895

**BUSINESS ADDRESS:**
- **STREET 1:** 399 BOYLSTON STREET
- **STREET 2:** SUITE 1100
- **CITY:** BOSTON
- **STATE:** MA
- **ZIP:** 02142
- **BUSINESS PHONE:** 617-425-9200

**MAIL ADDRESS:**
- **STREET 1:** 399 BOYLSTON STREET
- **STREET 2:** SUITE 1100
- **CITY:** BOSTON
- **STATE:** MA
- **ZIP:** 02142
**ISSUER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Werewolf Therapeutics, Inc.
- **CENTRAL INDEX KEY:** 0001785530
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 823523180
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**BUSINESS ADDRESS:**
- **STREET 1:** 200 TALCOTT AVENUE
- **STREET 2:** 2ND FLOOR
- **CITY:** WATERTOWN
- **STATE:** MA
- **ZIP:** 02472
- **BUSINESS PHONE:** 617-952-0555

**MAIL ADDRESS:**
- **STREET 1:** 200 TALCOTT AVENUE
- **STREET 2:** 2ND FLOOR
- **CITY:** WATERTOWN
- **STATE:** MA
- **ZIP:** 02472

### UNITED STATES SECURITIES AND EXCHANGE COMMISSION
**Washington, D.C. 20549**

## FORM 4

### STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

[ ] Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

[x] Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

---

| | | |
|:---|:---|:---|
| **1. Name and Address of Reporting Person**<sup>*</sup><br>GADICKE ANSBERT<br><sub>(Last) (First) (Middle)</sub><br>C/O MPM BIOIMPACT LLC<br>399 BOYLSTON STREET, SUITE 1100<br><sub>(Street)</sub><br>BOSTON, MA 02116<br><sub>(City) (State) (Zip)</sub> | **3. Date of Earliest Transaction (Month/Day/Year)**<br>2025-11-07 | **5. Relationship of Reporting Person(s) to Issuer**<br>(Check all applicable)<br>[ ] Director [X] 10% Owner<br>[ ] Officer (give title below) [ ] Other (specify below)<br>_ _ |
| **2. Issuer Name and Ticker or Trading Symbol**<br>Werewolf Therapeutics, Inc. [ HOWL ] | **4. If Amendment, Date of Original Filed (Month/Day/Year)**<br>  | **6. Individual or Joint/Group Filing (Check Applicable Line)**<br>[ ] Form filed by One Reporting Person<br>[X] Form filed by More than One Reporting Person |

---

---

| | | |
|:---|:---|:---|
| **1. Name and Address of Reporting Person**<sup>*</sup><br>MPM ONCOLOGY INNOVATIONS FUND LP<br><sub>(Last) (First) (Middle)</sub><br>C/O MPM BIOIMPACT LLC<br>399 BOYLSTON STREET, SUITE 1100<br><sub>(Street)</sub><br>BOSTON, MA 02116<br><sub>(City) (State) (Zip)</sub> | **3. Date of Earliest Transaction (Month/Day/Year)**<br>2025-11-07 | **5. Relationship of Reporting Person(s) to Issuer**<br>(Check all applicable)<br>[ ] Director [X] 10% Owner<br>[ ] Officer (give title below) [ ] Other (specify below)<br>_ _ |
| **2. Issuer Name and Ticker or Trading Symbol**<br>Werewolf Therapeutics, Inc. [ HOWL ] | **4. If Amendment, Date of Original Filed (Month/Day/Year)**<br>  | **6. Individual or Joint/Group Filing (Check Applicable Line)**<br>[ ] Form filed by One Reporting Person<br>[X] Form filed by More than One Reporting Person |

---

---

| | | |
|:---|:---|:---|
| **1. Name and Address of Reporting Person**<sup>*</sup><br>UBS Oncology Impact Fund L.P.<br><sub>(Last) (First) (Middle)</sub><br>C/O MPM BIOIMPACT LLC<br>399 BOYLSTON STREET, SUITE 1100<br><sub>(Street)</sub><br>BOSTON, MA 02116<br><sub>(City) (State) (Zip)</sub> | **3. Date of Earliest Transaction (Month/Day/Year)**<br>2025-11-07 | **5. Relationship of Reporting Person(s) to Issuer**<br>(Check all applicable)<br>[ ] Director [X] 10% Owner<br>[ ] Officer (give title below) [ ] Other (specify below)<br>_ _ |
| **2. Issuer Name and Ticker or Trading Symbol**<br>Werewolf Therapeutics, Inc. [ HOWL ] | **4. If Amendment, Date of Original Filed (Month/Day/Year)**<br>  | **6. Individual or Joint/Group Filing (Check Applicable Line)**<br>[ ] Form filed by One Reporting Person<br>[X] Form filed by More than One Reporting Person |

---

---

| | | |
|:---|:---|:---|
| **1. Name and Address of Reporting Person**<sup>*</sup><br>Oncology Impact Fund (Cayman) Management L.P.<br><sub>(Last) (First) (Middle)</sub><br>C/O MPM BIOIMPACT LLC<br>399 BOYLSTON STREET, SUITE 1100<br><sub>(Street)</sub><br>BOSTON, MA 02116<br><sub>(City) (State) (Zip)</sub> | **3. Date of Earliest Transaction (Month/Day/Year)**<br>2025-11-07 | **5. Relationship of Reporting Person(s) to Issuer**<br>(Check all applicable)<br>[ ] Director [X] 10% Owner<br>[ ] Officer (give title below) [ ] Other (specify below)<br>_ _ |
| **2. Issuer Name and Ticker or Trading Symbol**<br>Werewolf Therapeutics, Inc. [ HOWL ] | **4. If Amendment, Date of Original Filed (Month/Day/Year)**<br>  | **6. Individual or Joint/Group Filing (Check Applicable Line)**<br>[ ] Form filed by One Reporting Person<br>[X] Form filed by More than One Reporting Person |

---

---

| | | |
|:---|:---|:---|
| **1. Name and Address of Reporting Person**<sup>*</sup><br>MPM BioImpact LLC<br><sub>(Last) (First) (Middle)</sub><br>C/O MPM BIOIMPACT LLC<br>399 BOYLSTON STREET, SUITE 1100<br><sub>(Street)</sub><br>BOSTON, MA 02116<br><sub>(City) (State) (Zip)</sub> | **3. Date of Earliest Transaction (Month/Day/Year)**<br>2025-11-07 | **5. Relationship of Reporting Person(s) to Issuer**<br>(Check all applicable)<br>[ ] Director [X] 10% Owner<br>[ ] Officer (give title below) [ ] Other (specify below)<br>_ _ |
| **2. Issuer Name and Ticker or Trading Symbol**<br>Werewolf Therapeutics, Inc. [ HOWL ] | **4. If Amendment, Date of Original Filed (Month/Day/Year)**<br>  | **6. Individual or Joint/Group Filing (Check Applicable Line)**<br>[ ] Form filed by One Reporting Person<br>[X] Form filed by More than One Reporting Person |

---

---

| | | |
|:---|:---|:---|
| **1. Name and Address of Reporting Person**<sup>*</sup><br>MPM Oncology Innovations Fund GP LLC<br><sub>(Last) (First) (Middle)</sub><br>C/O MPM BIOIMPACT LLC<br>399 BOYLSTON STREET, SUITE 1100<br><sub>(Street)</sub><br>BOSTON, MA 02116<br><sub>(City) (State) (Zip)</sub> | **3. Date of Earliest Transaction (Month/Day/Year)**<br>2025-11-07 | **5. Relationship of Reporting Person(s) to Issuer**<br>(Check all applicable)<br>[ ] Director [X] 10% Owner<br>[ ] Officer (give title below) [ ] Other (specify below)<br>_ _ |
| **2. Issuer Name and Ticker or Trading Symbol**<br>Werewolf Therapeutics, Inc. [ HOWL ] | **4. If Amendment, Date of Original Filed (Month/Day/Year)**<br>  | **6. Individual or Joint/Group Filing (Check Applicable Line)**<br>[ ] Form filed by One Reporting Person<br>[X] Form filed by More than One Reporting Person |

---

---

| | | |
|:---|:---|:---|
| **1. Name and Address of Reporting Person**<sup>*</sup><br>MPM ASSET MANAGEMENT LLC<br><sub>(Last) (First) (Middle)</sub><br>C/O MPM BIOIMPACT LLC<br>399 BOYLSTON STREET, SUITE 1100<br><sub>(Street)</sub><br>BOSTON, MA 02116<br><sub>(City) (State) (Zip)</sub> | **3. Date of Earliest Transaction (Month/Day/Year)**<br>2025-11-07 | **5. Relationship of Reporting Person(s) to Issuer**<br>(Check all applicable)<br>[ ] Director [X] 10% Owner<br>[ ] Officer (give title below) [ ] Other (specify below)<br>_ _ |
| **2. Issuer Name and Ticker or Trading Symbol**<br>Werewolf Therapeutics, Inc. [ HOWL ] | **4. If Amendment, Date of Original Filed (Month/Day/Year)**<br>  | **6. Individual or Joint/Group Filing (Check Applicable Line)**<br>[ ] Form filed by One Reporting Person<br>[X] Form filed by More than One Reporting Person |

---

## Table I - Non-Derivative Securities

---

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| 1. Title of Security | 2. Transaction Date | 2A. Deemed Execution Date | 3. Transaction Code (V) | 3. Transaction Code (V) | 4. Securities Acquired (A) or Disposed of (D) | 4. Securities Acquired (A) or Disposed of (D) | 4. Securities Acquired (A) or Disposed of (D) | 5. Amount of Securities Beneficially Owned | 6. Ownership Form | 7. Nature of Indirect Beneficial Ownership |
| 1. Title of Security | 2. Transaction Date | 2A. Deemed Execution Date | Code | V | Amount | (A) or (D) | Price | 5. Amount of Securities Beneficially Owned | 6. Ownership Form | 7. Nature of Indirect Beneficial Ownership |
| Common Stock | 2025-11-07 |  | S<sup>(1)</sup> |  | 68480<sup>(2)</sup> | D | 1.11<sup>(3)</sup> | 5836240 | I | See Footnotes<sup>(4)(5)</sup> |
| Common Stock | 2025-11-10 |  | S<sup>(1)</sup> |  | 48570<sup>(6)</sup> | D | 1.18<sup>(7)</sup> | 5787670 | I | See Footnotes<sup>(4)(8)</sup> |
| Common Stock | 2025-11-11 |  | S<sup>(1)</sup> |  | 55810<sup>(9)</sup> | D | 1.14<sup>(10)</sup> | 5731860 | I | See Footnotes<sup>(4)(11)</sup> |
| Common Stock | 2025-11-12 |  | S<sup>(1)</sup> |  | 40669<sup>(12)</sup> | D | 1.09<sup>(13)</sup> | 5691191 | I | See Footnotes<sup>(4)(14)</sup> |

---

## Table II - Derivative Securities

---

|  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| 1. Title of Derivative Security | 2. Conversion or Exercise Price | 3. Transaction Date | 3A. Deemed Execution Date | 4. Transaction Code (V) | 4. Transaction Code (V) | 5. Number of Derivative Securities Acquired (A) or Disposed of (D) | 5. Number of Derivative Securities Acquired (A) or Disposed of (D) | 6. Date Exercisable and Expiration Date | 6. Date Exercisable and Expiration Date | 7. Title and Amount of Underlying Securities | 7. Title and Amount of Underlying Securities | 8. Price of Derivative Security | 9. Number of Derivative Securities Beneficially Owned | 10. Ownership Form | 11. Nature of Indirect Beneficial Ownership |
| 1. Title of Derivative Security | 2. Conversion or Exercise Price | 3. Transaction Date | 3A. Deemed Execution Date | Code | V | (A) | (D) | Date Exercisable | Expiration Date | Title | Amount or Number of Shares | 8. Price of Derivative Security | 9. Number of Derivative Securities Beneficially Owned | 10. Ownership Form | 11. Nature of Indirect Beneficial Ownership |
|  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |

---

### Footnotes:

(1) Transaction effected pursuant to a plan established pursuant to Rule 10b5-1 dated September 24, 2025.

(2) The shares were sold as follows: 4,702 by MPM Asset Management LLC ("AM LLC"), 29,704 by MPM BioVentures 2014, L.P. ("BV 2014"), 1,981 by MPM BioVentures 2014(B), L.P. ("BV 2014(B)"), 1,022 by MPM Asset Management Investors BV2014 LLC ("AM
BV2014"), 6,541 by MPM Oncology Innovations Fund, L.P. ("MPM OIF") and 24,530 by UBS Oncology Impact Fund L.P. ("UBS Oncology").

(3) The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1.075 to $1.188 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

(4) MPM BioVentures 2014 GP LLC and MPM BioVentures 2014 LLC ("BV LLC") are the direct and indirect general partners of BV 2014 and BV 2014(B). BV LLC is the manager of AM BV2014. MPM Oncology Innovations Fund GP LLC ("MPM OIF GP") is thegeneral partner of MPM OIF. MPM BioImpact LLC ("BioImpact") is the General Partner of Oncology Impact Fund (Cayman) Management L.P., the General Partner of UBS Oncology. Ansbert Gadicke is a member of AM LLC, a managing director of BV LLC, a managerof MPM OIF GP and the managing partner of BioImpact. Each Reporting Person disclaims beneficial ownership of the securities except to the extent of his or its pecuniary interest therein.

(5) The shares are held as follows: 400,824 by AM LLC, 2,531,366 by BV 2014, 168,839 by BV 2014(B), 87,127 by AM BV2014, 555,368 by MPM OIF and 2,092,716 by UBS Oncology.

(6) The shares were sold as follows: 3,335 by AM LLC, 21,067 by BV 2014, 1,405 by BV 2014(B), 725 by AM BV2014, 4,640 by MPM OIF and 17,398 by UBS Oncology.

(7) The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1.145 to $1.21 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

(8) The shares are held as follows: 397,489 by AM LLC, 2,510,299 by BV 2014, 167,434 by BV 2014(B), 86,402 by AM BV2014, 550,728 by MPM OIF and 2,075,318 by UBS Oncology.

(9) The shares were sold as follows: 3,832 by AM LLC, 24,208 by BV 2014, 1,615 by BV 2014(B), 832 by AM BV2014, 5,331 by MPM OIF and 19,992 by UBS Oncology.

(10) The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1.115 to $1.17 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

(11) The shares are held as follows: 393,657 by AM LLC, 2,486,091 by BV 2014, 165,819 by BV 2014(B), 85,570 by AM BV2014, 545,397 by MPM OIF and 2,055,326 by UBS Oncology.

(12) The shares were sold as follows: 2,792 by AM LLC, 17,640 by BV 2014, 1,177 by BV 2014(B), 607 by AM BV2014, 3,885 by MPM OIF and 14,568 by UBS Oncology.

(13) The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1.065 to $1.145 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the
Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

(14) The shares are held as follows: 390,865 by AM LLC, 2,468,451 by BV 2014, 164,642 by BV 2014(B), 84,963 by AM BV2014, 541,512 by MPM OIF and 2,040,758 by UBS Oncology.

**Remarks:**
This filing is 1 of 2 identical filings due to limitations on number of Reporting Persons. See Form 4 filed by MPM BioVentures 2014, L.P.

**Signature:** /s/ Ansbert Gadicke, Manager of MPM Oncology Innovations Fund GP LLC, the GP of MPM Oncology Innovations Fund, L.P.  
**Date:** 2025-11-12

**Signature:** /s/ Ansbert Gadicke, Manager of MPM Oncology Innovations Fund GP LLC  
**Date:** 2025-11-12

**Signature:** /s/ Ansbert Gadicke, Managing Partner of MPM BioImpact LLC  
**Date:** 2025-11-12

**Signature:** /s/ Ansbert Gadicke, member of MPM Asset Management LLC  
**Date:** 2025-11-12

**Signature:** /s/ Ansbert Gadicke  
**Date:** 2025-11-12

**Signature:** /s/ Ansbert Gadicke, Managing Partner of MPM BioImpact LLC, the GP of Oncology Impact Fund (Cayman) Management L.P., the GP of UBS Oncology Impact Fund, L.P.  
**Date:** 2025-11-12

**Signature:** /s/ Ansbert Gadicke, Managing Partner of MPM BioImpact LLC, the GP of Oncology Impact Fund (Cayman) Management L.P.  
**Date:** 2025-11-12

### Remarks:

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

**Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.**